Income Statement Presentation 2023

2022: Operating free cash flow and margin OFCF -8% driven by movements in NWC and higher investments in IA Roche 36.9% % of sales 34.6% 30.9% 31.1% 27.9% 25.4% -2.4%p¹ 19.0% -3.1%p¹ 14.4% 11.4% -4.5%p¹ -8%¹ CHFM 19,411 -4%¹ 17,673 16,639 15,753 14,815 13,853 2020 2021 2022 Roche Group 1 At CER=Constant Exchange Rates Pharma Division -21%¹ 3,370 2,561 1,571 Diagnostics Division 62

View entire presentation